HemOnc Today New York

The latest news from the annual meeting, including video perspective from faculty members and attendees.


Immunotherapy likely to become standard for recurrent/metastatic head and neck cancers

March 22, 2019
The standard treatment for patients with recurrent or metastatic head and neck cancers is expected to change from chemotherapy to immunotherapy based…
Meeting News

Cisplatin superior to cetuximab for locally advanced head and neck cancer

March 22, 2019
NEW YORK — Cisplatin appears to be superior to cetuximab for patients with locally advanced head and neck cancer regardless of HPV status…
Meeting News

Genetic testing can detect melanoma earlier, but tailored approach is required

March 21, 2019
Genetic testing can help increase early detection of melanoma among patients and their family members, according to a presenter at HemOnc Today New…
Meeting News

Standards evolve for adjuvant therapy of melanoma

March 21, 2019
NEW YORK — A strong rationale exists for offering adjuvant therapy to certain patients with melanoma, but several aspects of treatment remain…
Meeting News

More immunotherapy regimens ‘desperately needed’ for salvage treatment of advanced NSCLC

March 21, 2019
NEW YORK — Results of the KEYNOTE-189 trial dramatically altered initial treatment for patients with advanced-stage non-small cell lung cancer…
Meeting News

Immunotherapy-chemotherapy combination should be first-line treatment for many patients with NSCLC

March 21, 2019
NEW YORK — A combination of immunotherapy and chemotherapy should be used as first line treatment for many patients with non-small cell lung…
Meeting News

Lung cancer ‘personifies precision medicine’

March 21, 2019
NEW YORK — Precision medicine approaches have dramatically altered treatment approaches and improved outcomes for patients with lung cancer…
Meeting News

HemOnc Today New York uses ‘practical, interactive approach’ to help providers improve cancer care

March 6, 2019
HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives on advances in cancer treatment. …
Meeting News

BRAF/MEK inhibitor therapy a preferred option for metastatic melanoma

March 26, 2018
NEW YORK — Combination therapy with BRAF and MEK inhibitors can confer long-term survival for patients with low-burden metastatic melanoma and…
Meeting NewsVideo

VIDEO: CAR T cells effective for non-Hodgkin lymphoma

March 13, 2018
NEW YORK — In this video commentary from HemOnc Today New York, Stephen J. Schuster, MD, discusses treatment with CD19-directed chimeric…